Gilbert W Gleim

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild t
    Gilbert W Gleim
    Merck Research Laboratories, Merck and Co, Inc, Blue Bell, Pennsylvania, USA
    Clin Ther 28:1639-48. 2006
  2. ncbi request reprint The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy
    Jonathan C Fox
    Merck Research Laboratories, BLX 21, P O Box 4, West Point, PA 19486, USA
    J Clin Hypertens (Greenwich) 6:437-42; quiz 443-4. 2004
  3. ncbi request reprint Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Zhongxin Zhang
    Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
    J Am Soc Nephrol 16:1775-80. 2005
  4. ncbi request reprint Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am J Cardiovasc Drugs 5:17-22. 2005
  5. ncbi request reprint Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
    J Am Soc Nephrol 18:1540-6. 2007
  6. ncbi request reprint Effects of losartan on diabetic maculopathy in type 2 diabetic patients
    Gilbert W Gleim
    J Intern Med 255:304-5; author reply 306-7. 2004
  7. ncbi request reprint The impact of morbid events on survival following hospitalization for complicated myocardial infarction
    Kenneth Dickstein
    University of Bergen, Cardiology Division, Stavanger University Hospital, 4011, Stavanger, Norway
    Eur J Heart Fail 8:74-80. 2006

Detail Information

Publications7

  1. ncbi request reprint A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild t
    Gilbert W Gleim
    Merck Research Laboratories, Merck and Co, Inc, Blue Bell, Pennsylvania, USA
    Clin Ther 28:1639-48. 2006
    ..Because patients with hypertension may require >1 antihypertensive agent to control blood pressure (BP), physicians often prescribe a fixed combination of antihypertensive medications...
  2. ncbi request reprint The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy
    Jonathan C Fox
    Merck Research Laboratories, BLX 21, P O Box 4, West Point, PA 19486, USA
    J Clin Hypertens (Greenwich) 6:437-42; quiz 443-4. 2004
    ..The use of two medications will achieve goal BP in more patients than monotherapy. This observation is important in treatment of high-risk patients with diabetes...
  3. ncbi request reprint Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
    Zhongxin Zhang
    Merck and Co, Inc, P O Box 4, BL 3 4, West Point, PA 19486, USA
    J Am Soc Nephrol 16:1775-80. 2005
    ....
  4. ncbi request reprint Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide
    Sverre E Kjeldsen
    Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    Am J Cardiovasc Drugs 5:17-22. 2005
    ..Fixed combination ARB/hydrochlorothiazide agents make sense as initial therapy for patients in whom BP is >20/10 mm Hg above goal...
  5. ncbi request reprint Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Wouter B A Eijkelkamp
    Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
    J Am Soc Nephrol 18:1540-6. 2007
    ..Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may therefore require a dual strategy, targeting both SBP and albuminuria reduction...
  6. ncbi request reprint Effects of losartan on diabetic maculopathy in type 2 diabetic patients
    Gilbert W Gleim
    J Intern Med 255:304-5; author reply 306-7. 2004
  7. ncbi request reprint The impact of morbid events on survival following hospitalization for complicated myocardial infarction
    Kenneth Dickstein
    University of Bergen, Cardiology Division, Stavanger University Hospital, 4011, Stavanger, Norway
    Eur J Heart Fail 8:74-80. 2006
    ..Little is known about the importance of morbid events with respect to longer term survival following MI hospital discharge...